Company intelligence / Profile preview

Revitin Life Sciences LLC

New York, New York, United Statesrevitin.com ↗

Ownership: Private
Employees: ~5
Development stage: Commercial

Overview

Clinical results show that use of Revitin toothpaste reduces gingival inflammation by up to 42%, plaque by up to 46%, and bleeding by up to 72.5% compared to leading brands. The formula has been developed over more than fifteen years of clinical research focused on supporting the oral microbiome using natural prebiotic ingredients.

Therapeutic areas: OtherDermatologyInfectious Diseases
Modalities: Non-pharmacological therapy (prebiotic oral care)Device (toothpaste as a delivery vehicle for prebiotics and nutrients)Prebiotic therapy (oral microbiome modulation)
Industry: Consumable Medical Devices

Drug pipeline

1 asset

Revitin

Commercial

Indications: Oral health

Beyond the preview

Go deeper on Revitin Life Sciences LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Revitin Life Sciences LLC.

Explore the full profile